The EAACI/GA2LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update
The EAACI/GA2LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update
复制标题
DOI：
10.1111/all.12313
复制
发表时间：
2014-07-01
期刊：
影响因子：
12.4
通讯作者：
Maurer, M.
中科院分区：
文献类型：
--
作者：
Zuberbier, T.;Aberer, W.;Maurer, M.
本指南是采用“建议评估、发展和评价分级”（GRADE）方法进行系统文献综述的结果，并于2012年11月28日和29日在柏林举行了结构化共识会议。它是由欧洲过敏和临床免疫学学会皮肤病科（EAACI）、欧盟资助的卓越网络、全球过敏和哮喘欧洲网络（GA(2)LEN）、欧洲皮肤病论坛（EDF）和世界过敏组织（WAO）联合发起的，有21个国家和国际学会的代表参加。荨麻疹是一种常见的肥大细胞驱动疾病，表现为荨麻疹、血管性水肿或两者兼而有之。急性荨麻疹的终生患病率约为20%。慢性自发性荨麻疹和其他慢性形式的荨麻疹不仅会导致生活质量下降，而且还会影响工作和学习表现，因此属于严重过敏性疾病的成员。本指南涵盖了荨麻疹的定义和分类，并考虑到在确定其病因、诱发因素和病理机制方面的最新进展。此外，它概述了针对不同亚型荨麻疹的循证诊断和治疗方法。该指南得到了欧洲医学专家联盟（UEMS）的认可和接受。
This guideline is the result of a systematic literature review using the 'Grading of Recommendations Assessment, Development and Evaluation' (GRADE) methodology and a structured consensus conference held on 28 and 29 November 2012, in Berlin. It is a joint initiative of the Dermatology Section of the European Academy of Allergy and Clinical Immunology (EAACI), the EU-funded network of excellence, the Global Allergy and Asthma European Network (GA(2)LEN), the European Dermatology Forum (EDF), and the World Allergy Organization (WAO) with the participation of delegates of 21 national and international societies. Urticaria is a frequent, mast cell-driven disease, presenting with wheals, angioedema, or both. The life-time prevalence for acute urticaria is approximately 20%. Chronic spontaneous urticaria and other chronic forms of urticaria do not only cause a decrease in quality of life, but also affect performance at work and school and, as such, are members of the group of severe allergic diseases. This guideline covers the definition and classification of urticaria, taking into account the recent progress in identifying its causes, eliciting factors and pathomechanisms. In addition, it outlines evidence-based diagnostic and therapeutic approaches for the different subtypes of urticaria. This guideline was acknowledged and accepted by the European Union of Medical Specialists (UEMS).